How to choose tender management software for pharma and medical device companies

This guide is for the companies that bid: the manufacturer or distributor that submits offers to supply medicines, medical devices, or healthcare services. It is not about the platform a public body, a health authority, or a hospital uses to publish and run its procedures, because that is a different tool, designed for a different set of needs. The distinction is essential, because "tender software" can mean two very different perspectives. Before choosing the right solution, you first need to know which side of the table you sit on.

For the companies that bid, tendering is not a simple administrative function. It is a genuine sales channel. In medical devices, tenders account for 70% to 85% of revenue; in pharmaceuticals, for 25% to 40%. This is where a company consolidates, wins, or loses market share, and yet the choice of the tool to manage it is still too often approached as if it were the purchase of a secondary piece of software or an appendix to the business system.

The most common mistake is not choosing the wrong software. It is adopting none at all, and trying to cover the need with tools already in the company or seemingly close at hand: a shared spreadsheet, a module of the business system, or a notice-alert service. These shortcuts can seem quick and sufficient, at least while the number of tenders stays limited. Beyond that point, the cost of inefficiencies, errors, and missed opportunities can far exceed that of a solution built specifically for tender management. This guide sets out the criteria for understanding when the moment to adopt one has come, and how to choose the right one.

As noted, almost every company starts by managing tenders with the tools it already has, and sooner or later runs into their limits. It helps to recognise the three most common shortcuts, because each can answer one specific need while leaving essential parts of the process uncovered, the parts that decide whether you can govern it and compete effectively.

The do-it-yourself approach

Spreadsheets, shared folders, reminders kept by hand. It is immediate, seemingly simple, and close to free. But it is not built to handle complexity at scale. When tenders reach dozens in parallel, with overlapping deadlines and specifications running to hundreds of pages, manual handling shows its limits fast: a notice that slips through, a deadline forgotten, a new version of the documents that no one noticed. And that is before the know-how problem, where the knowledge lives entirely inside specific individuals and leaves with them.

Extending a CRM or ERP

This is perhaps the most deceptive shortcut, because it often looks the most rational: rely on what the company already owns. But a CRM is built to manage the customer relationship, and an ERP to run master data, orders, and administrative processes. They can certainly store some tender-related information, but they neither understand its specific logic nor can they govern its full complexity: they do not natively handle lots, active ingredients, specifications, documentary requirements, reference prices, or award criteria. They are effective in their own domain, yet they cover mostly what comes before or after the tender, not the whole decision-making and operational process needed to prepare a competitive bid, reach award, and manage the stages that follow.

The generalist procurement-monitoring tool

It answers the initial need, almost always by focusing on finding and flagging new notices. It is useful for knowing that a tender exists, but not necessarily for deciding whether to bid, shaping the offer strategy, and building a competitive proposal. As a rule it does not analyse the documentation in depth, does not support pricing decisions, and does not translate the regulatory, commercial, and organisational specifics of the pharmaceutical and medical device sector into a structured operational process. It partly solves the first problem, spotting the opportunity, but leaves the company to handle all the ones that follow.

To be clear, none of these tools is useless in absolute terms. The point is that they cover only the most visible part of the process, leaving the harder, decisive steps uncovered: analysing the requirements, shaping the offer and positioning it against bids already in play, coordinating internally, and setting prices and discounts according to the criteria the specification lays down. And these are exactly the areas where, in pharmaceuticals and medical devices, a tender is won or lost.

The reason a generic tool falls short is not necessarily the quality of the software itself, but the specific grammar of the sector. Life sciences tenders rely on classifications, codes, and relationships between products that a horizontal solution, unless properly specialised, was not designed to handle.

On the pharmaceutical side, a tender can be structured by marketing authorisation number, active ingredient and ATC code, dosage, pharmaceutical form, and pack, with equivalences between packs and the distinction between originator, generic, and biosimilar. On the medical device side, the reference points are the national device registry, the device nomenclature (such as Italy's CND), and registration numbers, each with its own risk class. A software that does not master this structure can store information but struggles to organise and govern it according to the actual logic of the tender. The risk is that it forces products, families, hierarchies, lots, and requirements into far more generic categories, introducing approximations that translate into errors of assessment or of offer construction.

On top of this comes the award logic. EU Directive 2014/24, transposed into each country's public-procurement law, distinguishes between award to the lowest price and the most economically advantageous tender (MEAT), where price sits alongside criteria such as quality, supply conditions, and service. Understanding from the outset which scheme a tender will be judged on changes the way the offer has to be reasoned, prepared, and built.

A dedicated vertical solution exists first to resolve the complexities of the tender process, and to ease the work of the downstream systems that handle orders and, later, invoicing. So, having established why a vertical solution can make the difference, the question becomes how to assess one. The most useful test is simple: distinguish what a basic tool merely records from what a solution must be able to understand, govern, and support across the entire tender process.

Coverage of tender sources and tracking of updates

Tenders in this sector are published across diverse, fragmented sources: TED for European notices, national procurement databases, national e-procurement platforms and dynamic purchasing systems for medicines, regional purchasing bodies, and the portals of local health authorities and hospitals. A basic tool captures the initial notice and stops. An adequate one keeps up with everything that comes afterwards: corrections, extensions, clarifications, attachments. The difference shows most in the critical moments, when a correction moves a deadline or changes a requirement a few days before the close. In those cases the software has to detect the update, link it correctly to the tender, keep a record of it, and promptly alert the people involved, so the team does not keep working on information that is already out of date.

Reading tender documents

A specification can run to hundreds of pages of technical and regulatory requirements. A basic tool leaves people to work through them and reconstruct the relevant content entirely by hand. An adequate solution extracts requirements, evaluation criteria, and deadlines reliably and verifiably, putting the people who work on the tender in a position to check the output rather than rebuild it from scratch. The value is not in replacing human oversight, but in letting the team focus on verifying and assessing the information instead of having to locate and reconstruct it manually.

End-to-end workflow and approvals

Life sciences tenders involve several company functions: Regulatory, Market Access, Supply Chain, Finance, and Commercial all look at the same offer. In a basic tool, individual features stay largely disconnected and the process keeps living in emails, shared files, and informal handoffs of information. An adequate solution instead governs the entire tender workflow, assigning tasks, responsibilities, and approval levels, tracking progress, and keeping deadlines in view. The goal is to ensure that every offer is completed and approved through the required steps, with no omissions, bottlenecks, or submissions past the deadline.

Pricing intelligence

Price, in life sciences, is not simply a value to lower until the offer becomes competitive. Reference prices come into play, along with price erosion after loss of exclusivity, analysis by lot and by cluster, comparison with the history of awards and, where the data is lawfully accessible, information on competitors' positioning. A basic tool merely offers a field in which to type a number. An adequate solution instead provides data, comparisons, and simulations that help work out which price is consistent with the market, with the company's objectives, and with the acceptable level of risk, before the offer is approved and submitted.

Continuity of supply

Almost every tender in the sector gives rise to multi-year contracts. Committing to supply given quantities for years without first checking that it is sustainable is a real operational and financial risk. An adequate solution links the offer to actual availability: required quantities, forecasts, stock, lead times, and production capacity. On the pharmaceutical side the issue is significant enough that the European Medicines Agency monitors the availability of products through a dedicated platform, because shortages have a direct impact on patient care. Checking that supply is sustainable before submitting the offer, rather than after award, means reducing the risk of shortages, defaults, penalties, and reputational damage.

Ability to handle high volumes

A basic tool can be adequate while tenders are few and the number of documents, users, and activities stays limited. But when the procedures to follow reach dozens in parallel, with bulky specifications, frequent updates, and several company functions involved, slowdowns, inefficiencies, and loss of control start to appear. An adequate solution is built to operate at scale, maintaining performance, traceability, and reliability even with large volumes of data and simultaneous activity. It does not just handle a handful of cases; it carries the real operational load the sector generates.

Security, permissions, and traceability

Tender data, from prices to commercial terms, is sensitive information, and it should always be accessible only to authorised people. A basic tool offers undifferentiated access and rarely "remembers" who did what. An adequate solution instead distinguishes roles and authorisation levels, controls access to information, and keeps a complete, verifiable audit trail of changes, decisions, and approvals. That traceability is essential when you need to reconstruct, even long afterwards, who made a given decision, on the basis of what information, and through which approval steps, guaranteeing at any moment a full account of what happened and who did what, to the clear benefit of compliance and audit.

Integration with company systems

In life sciences, tender management lives around business-critical processes, often on complex business systems such as SAP. A basic tool exchanges data only through manual exports, which introduce errors and delays. An adequate solution instead integrates with the existing systems, so that the tender does not remain an isolated process but becomes part of the company's commercial, operational, and administrative activity. Importing master data, price lists, and order data, exporting prices and validity periods, commercial terms, special notes, and bulk updates: everything feeds a constant, tight, linear, zero-error flow, with a clear benefit across the whole internal chain.

International scale

For companies operating in more than one country, the ability to manage tenders across different clusters, each with different languages, regulations, information sources, classifications, and local practices, is not an optional feature but an essential requirement. An adequate solution makes it possible to apply common processes, rules, and levels of control, while leaving local organisations the flexibility they need to operate according to the specifics of their own market. Only then can a company achieve consolidated visibility, operational consistency, and comparison across countries without flattening differences and needs tied to compliance and legal matters that, in tendering, directly affect how offers are built and managed.

The thread running through all these criteria is a single question: are you choosing the tool based on what is easiest to extend from the systems already in place, or based on what the tendering segment of the sector genuinely needs? This is the difference between choosing for extension and choosing for depth, and the first path almost always leads to a compromise that presents its bill sooner or later.

The question becomes even more relevant with the spread of artificial intelligence. As models and technologies become accessible to a growing number of vendors, the real differentiator is no longer the mere presence of AI. What makes the difference is domain knowledge, the quality and depth of the available data, and the ability to embed artificial intelligence within already-structured business processes. A generalist extension can add AI features, but it does not thereby acquire the vertical expertise needed to interpret the complexity of tendering in life sciences correctly.

So it is worth not mistaking substance for showcase. A platform that looks less striking, but is built on reliable data, controlled workflows, sector rules, and solid integrations, can deliver more value than one built mainly around impressive dashboards and isolated AI features. Artificial intelligence does not replace a sound application foundation: it amplifies its value, provided it rests on consistent data, governed processes, and real knowledge of the sector.

None of these qualities can be judged by watching a sales demo, built to show the product in its best light. The serious way to choose is to put the tool to the test on your own real specifications, the ones the company works with every day, and to watch it in the situations that genuinely put it under pressure: a tender with many lots, a correction published close to the deadline, an offer that needs the contribution and approval of several company functions, or an update that changes requirements already analysed. Asking the vendor to demonstrate the whole path, from detecting the notice to final archiving, lets you judge the soundness of the process far better than any list of features.

Before committing to a possible project, it is worth answering a few essential questions honestly.

• Does the tool genuinely distinguish a pharmaceutical tender from one for medical devices, or does it apply the same evaluation model to both?
• Does it handle reference prices, the history of awards, and price-erosion dynamics after loss of exclusivity, or does it merely record the price entered?
• Does it catch corrections, extensions, clarifications, and new attachments, keeping current the information the team is working on?
• Does it analyse tender documents and extract requirements, evaluation criteria, and deadlines in a structured, verifiable way?
• Does it govern tasks, responsibilities, and approvals, preventing an offer from being submitted without the required steps or past the deadline?
• Does it let you check that supply is sustainable before committing to the contracting authority?
• Does it integrate bidirectionally with the ERP and the company's other systems, or does it keep the tender separate from the rest of the processes?
• Does it protect sensitive information through roles, granular permissions, and a complete audit trail?
• Can it sustain high volumes and multi-country operations without losing control, performance, and local adaptability?
• Are you choosing it because it genuinely meets the needs of tendering, or because it is easier to extend a tool you already have?

The right choice is not the tool that appears to be the quickest to adopt, but the one able to understand and govern, in depth, the specifics of tenders in the sector. For a pharmaceutical or medical device company, tendering can represent a substantial, and in some cases the majority, share of revenue. The choice of the tool to manage it cannot therefore be reduced to a technical or IT decision: it bears directly on the company's ability to compete, protect margins, and ensure continuity of supply.

When tenders are a core part of the business, the software that governs them must be chosen as such.